Clopidogrel Teva: Uses, Dosage & Side Effects
An antiplatelet medicine that prevents blood clots in patients at risk of heart attack, stroke, or peripheral arterial disease
Clopidogrel Teva is a prescription antiplatelet medicine containing the active substance clopidogrel. It belongs to the thienopyridine class and works by irreversibly inhibiting the P2Y12 ADP receptor on platelets, thereby preventing platelet aggregation and reducing the risk of blood clots. Clopidogrel is widely used in patients who have experienced a myocardial infarction (heart attack), ischaemic stroke, or who have established peripheral arterial disease. It is also a cornerstone of dual antiplatelet therapy (DAPT) in combination with aspirin following acute coronary syndromes and coronary stent placement. Clopidogrel is listed on the WHO Model List of Essential Medicines and is one of the most prescribed cardiovascular drugs worldwide.
Quick Facts: Clopidogrel Teva
Key Takeaways
- Clopidogrel Teva is a P2Y12 receptor antagonist that irreversibly blocks ADP-mediated platelet aggregation, reducing the risk of atherothrombotic events in patients with cardiovascular disease.
- It is indicated for secondary prevention after myocardial infarction, ischaemic stroke, or in established peripheral arterial disease, and as part of dual antiplatelet therapy (DAPT) with aspirin after acute coronary syndrome or coronary stenting.
- Clopidogrel is a prodrug that requires hepatic activation via CYP2C19; patients who are CYP2C19 poor metabolizers may have reduced drug efficacy and may need alternative treatment.
- Concomitant use of omeprazole or esomeprazole should be avoided, as these proton pump inhibitors can reduce clopidogrel's antiplatelet effect by up to 45%; pantoprazole is a preferred alternative if gastroprotection is needed.
- The most common side effects are bleeding events (bruising, nosebleeds, gastrointestinal bleeding); patients should be counselled to report unusual bleeding and should not stop treatment without medical advice due to the risk of rebound thrombotic events.
What Is Clopidogrel Teva and What Is It Used For?
Clopidogrel Teva contains the active substance clopidogrel (as clopidogrel hydrogen sulfate), a thienopyridine-class antiplatelet agent. It is a generic formulation manufactured by Teva Pharmaceuticals, bioequivalent to the original branded product Plavix (developed by Sanofi). Clopidogrel has been one of the most widely prescribed cardiovascular medications globally since its original approval by the FDA in 1997 and by the EMA in 1998. It is included on the World Health Organization (WHO) Model List of Essential Medicines, recognizing its critical importance in preventing atherothrombotic events.
Atherothrombosis is the process by which blood clots form on the surface of ruptured or eroded atherosclerotic plaques within arteries. These clots can partially or completely obstruct blood flow, leading to life-threatening events such as myocardial infarction (heart attack), ischaemic stroke, or critical limb ischaemia. Platelets play a central role in this process: when an atherosclerotic plaque ruptures, subendothelial collagen and other prothrombotic substances are exposed, triggering platelet adhesion, activation, and aggregation. Activated platelets release adenosine diphosphate (ADP), which binds to P2Y12 receptors on the platelet surface, amplifying platelet activation and promoting the formation of a stable platelet-rich thrombus.
Clopidogrel is a prodrug that has no intrinsic antiplatelet activity. After oral administration, it is absorbed from the gastrointestinal tract and undergoes extensive hepatic metabolism. Approximately 85% of the absorbed dose is hydrolyzed by esterases in the blood and liver to an inactive carboxylic acid metabolite. The remaining 15% is oxidized by hepatic cytochrome P450 (CYP) enzymes in a two-step process to generate the active thiol metabolite. The first oxidation step is catalyzed primarily by CYP2C19, CYP1A2, and CYP2B6, while the second step is catalyzed mainly by CYP2C19, CYP2C9, CYP3A4, and CYP2B6. The active metabolite then binds selectively and irreversibly to the P2Y12 receptor on the platelet surface, blocking ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, which is the final common pathway for platelet aggregation. Because the binding is irreversible, the antiplatelet effect persists for the remaining lifespan of the platelet, approximately 7 to 10 days.
Clopidogrel Teva is indicated for the prevention of atherothrombotic events in the following clinical settings:
- Recent myocardial infarction (heart attack): Treatment can be started from a few days up to 35 days after the event. Clopidogrel reduces the risk of recurrent heart attack, ischaemic stroke, and vascular death.
- Recent ischaemic stroke: Treatment can be started from 7 days up to 6 months after the event. It is used for long-term secondary prevention of atherothrombotic events.
- Established peripheral arterial disease (PAD): Clopidogrel is an alternative to aspirin for patients with symptomatic PAD, including intermittent claudication.
- Acute coronary syndrome (ACS): In combination with aspirin, clopidogrel is used for patients with non-ST-segment elevation ACS (unstable angina or NSTEMI) and for patients with ST-segment elevation myocardial infarction (STEMI) who are eligible for thrombolytic therapy or who are managed medically.
- Coronary stent placement: Dual antiplatelet therapy with clopidogrel and aspirin is the standard of care after percutaneous coronary intervention (PCI) with stent implantation, to prevent stent thrombosis.
The evidence base for clopidogrel is extensive and includes several landmark clinical trials. The CAPRIE trial (Lancet, 1996) demonstrated that clopidogrel 75 mg daily was slightly more effective than aspirin 325 mg daily in reducing the composite endpoint of ischaemic stroke, myocardial infarction, or vascular death in patients with recent stroke, recent MI, or established PAD (relative risk reduction of 8.7%). The CURE trial (New England Journal of Medicine, 2001) established the benefit of adding clopidogrel to aspirin in patients with non-ST-elevation ACS, showing a 20% relative risk reduction in the composite of cardiovascular death, non-fatal MI, or stroke compared with aspirin alone. The COMMIT trial (Lancet, 2005) demonstrated the benefit of adding clopidogrel to aspirin in STEMI patients receiving fibrinolytic therapy.
Clopidogrel is included on the World Health Organization Model List of Essential Medicines, underscoring its global importance in cardiovascular disease prevention. It is considered a fundamental medication that should be available in all healthcare systems worldwide for preventing heart attacks, strokes, and other atherothrombotic events.
What Should You Know Before Taking Clopidogrel Teva?
Contraindications
Clopidogrel Teva must not be used in the following situations:
- Hypersensitivity: Known allergy to clopidogrel or any of the other ingredients in the tablet (see the Contents section below).
- Active pathological bleeding: Active bleeding such as peptic ulcer haemorrhage or intracranial haemorrhage. Clopidogrel inhibits platelet function and will worsen ongoing bleeding.
- Severe hepatic impairment: Severe liver disease that could impair the metabolism of clopidogrel and increase the risk of bleeding complications. The liver is essential for converting clopidogrel to its active metabolite, and severe impairment may paradoxically increase bleeding risk by impairing coagulation factor synthesis.
Warnings and Precautions
Clopidogrel increases the risk of bleeding. Seek immediate medical attention if you experience signs of unusual bleeding such as blood in your urine or stools, vomiting blood, coughing up blood, unexplained bruising, or bleeding that takes longer than usual to stop. Do not stop clopidogrel without consulting your doctor, as premature discontinuation – especially after coronary stenting – can lead to stent thrombosis, a potentially fatal complication.
Before starting clopidogrel, discuss the following with your healthcare provider:
- Planned surgery or dental procedures: Clopidogrel should typically be discontinued 5 to 7 days before elective surgery to allow recovery of normal platelet function. However, in patients with recent coronary stents, premature discontinuation carries the risk of stent thrombosis. The decision to stop clopidogrel before surgery requires careful assessment by both the surgeon and the cardiologist. Always inform your surgeon, anaesthetist, and dentist that you are taking clopidogrel.
- History of bleeding: If you have a history of gastrointestinal bleeding, intracranial haemorrhage, or other significant bleeding events, your doctor needs to weigh the benefits of antiplatelet therapy against the increased bleeding risk.
- Kidney disease: Limited experience exists with clopidogrel in patients with severe renal impairment. While no dose adjustment is specifically required, these patients should be monitored carefully as they may be at increased risk of bleeding.
- Liver disease: Mild to moderate hepatic impairment requires caution. Clopidogrel is metabolized by the liver, and impaired liver function may affect both the conversion to the active metabolite and the synthesis of coagulation factors.
- CYP2C19 poor metabolizer status: Patients with genetic variants resulting in reduced CYP2C19 function (poor metabolizers) produce less of the active metabolite and have diminished platelet inhibition. This occurs in approximately 2% of Caucasians and African Americans, and up to 15% of Asians. Your doctor may consider pharmacogenomic testing and may prescribe an alternative antiplatelet agent (such as prasugrel or ticagrelor) if testing reveals poor metabolizer status, particularly in high-risk clinical situations.
- Thrombotic thrombocytopenic purpura (TTP): This rare but serious condition has been reported with clopidogrel use, sometimes after only a short exposure. TTP requires immediate medical treatment including plasma exchange. Seek urgent medical attention if you develop purpura (purple spots on the skin), unexplained fever, severe fatigue, jaundice, or neurological symptoms while taking clopidogrel.
Pregnancy and Breastfeeding
Clopidogrel should preferably not be used during pregnancy. Animal studies have not shown direct harmful effects on pregnancy, embryonic or fetal development, parturition, or postnatal development. However, no adequate and well-controlled studies have been conducted in pregnant women. As a precaution, clopidogrel should only be used during pregnancy if the potential benefit clearly outweighs the potential risk to the fetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medication.
It is not known whether clopidogrel or its metabolites are excreted in human breast milk. Studies in rats have shown that clopidogrel and its metabolites are excreted in breast milk. Breastfeeding should be discontinued during treatment with clopidogrel. Discuss the options with your healthcare provider, weighing the importance of the medication to your health against the potential risk to the infant.
Driving and Operating Machinery
Clopidogrel is not expected to affect your ability to drive or operate machinery. No studies specifically evaluating the effect on driving ability have been performed, but based on the pharmacological profile and known side effects, impairment is unlikely. However, be aware that some rare side effects such as dizziness may affect individual patients. If you experience dizziness or confusion while taking clopidogrel, avoid driving or operating heavy machinery until these symptoms resolve.
How Does Clopidogrel Teva Interact with Other Drugs?
Because clopidogrel is a prodrug requiring hepatic CYP450 activation, drugs that inhibit or induce these enzymes – particularly CYP2C19 – can significantly alter its antiplatelet effect. In addition, combining clopidogrel with other agents that affect haemostasis increases the risk of bleeding. The following table summarizes the key drug interactions:
| Drug / Class | Interaction | Severity | Clinical Recommendation |
|---|---|---|---|
| Omeprazole / Esomeprazole | Inhibit CYP2C19, reducing active metabolite by up to 45% | Major | Avoid; use pantoprazole or lansoprazole instead |
| Warfarin / DOACs | Additive bleeding risk via different mechanisms | Major | Avoid unless specifically indicated; monitor closely |
| NSAIDs (ibuprofen, naproxen) | Increased risk of gastrointestinal bleeding | Major | Use with caution; consider gastroprotection |
| Aspirin (low-dose) | Synergistic antiplatelet effect; increased bleeding risk | Moderate | Used intentionally as DAPT; limit duration per guidelines |
| SSRIs / SNRIs | SSRIs inhibit serotonin uptake by platelets, increasing bleeding risk | Moderate | Monitor for bleeding; consider gastroprotection |
| Fluconazole / Fluvoxamine | CYP2C19 inhibition may reduce clopidogrel activation | Moderate | Use alternatives where possible; monitor platelet function |
| Rifampicin | CYP2C19 inducer; may increase active metabolite levels | Moderate | Monitor for increased bleeding; clinical significance unclear |
Major Interactions
The interaction between clopidogrel and proton pump inhibitors (PPIs), particularly omeprazole and esomeprazole, is one of the most clinically significant drug interactions in cardiology. Both the FDA and EMA have issued warnings about this interaction. Omeprazole and esomeprazole are potent inhibitors of CYP2C19, the primary enzyme responsible for converting clopidogrel to its active metabolite. Pharmacodynamic studies have demonstrated that concomitant use of omeprazole reduces the antiplatelet activity of clopidogrel by approximately 45%, as measured by platelet reactivity assays. While some observational studies have produced mixed results regarding the clinical consequences, regulatory agencies recommend avoiding omeprazole and esomeprazole in patients taking clopidogrel.
If gastroprotection is needed (for example, in patients on dual antiplatelet therapy who are at high risk of gastrointestinal bleeding), pantoprazole or lansoprazole are preferred alternatives because they have a much weaker inhibitory effect on CYP2C19. The COGENT trial demonstrated that omeprazole reduced gastrointestinal events in patients taking clopidogrel and aspirin, but this must be weighed against the potential reduction in antiplatelet efficacy.
Combining clopidogrel with oral anticoagulants such as warfarin or direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) significantly increases the risk of major bleeding. This combination (sometimes called "triple therapy") is occasionally necessary in patients with both atrial fibrillation requiring anticoagulation and recent coronary stenting requiring dual antiplatelet therapy. In such cases, current ESC guidelines recommend minimizing the duration of triple therapy (typically 1 week to 1 month), followed by dual therapy (one antiplatelet plus one anticoagulant), and using the lowest effective anticoagulant dose.
Minor Interactions
Morphine and other opioids may delay gastric emptying and intestinal absorption of oral medications, potentially reducing peak plasma levels of clopidogrel's active metabolite. In the setting of acute myocardial infarction where morphine is frequently administered for pain, this interaction may delay the onset of antiplatelet effect. Some clinicians recommend using a higher clopidogrel loading dose or considering intravenous antiplatelet alternatives (such as cangrelor) in this setting.
Grapefruit and grapefruit juice inhibit CYP3A4, one of the enzymes involved in clopidogrel activation. However, since CYP2C19 is the primary enzyme, the clinical significance of this interaction is considered minor. Nevertheless, patients are generally advised to consume grapefruit in moderation while taking clopidogrel.
Never stop taking clopidogrel without consulting your doctor. In patients with coronary stents, premature discontinuation of clopidogrel is the strongest risk factor for stent thrombosis, which can be fatal. If you need to have surgery or a dental procedure, discuss the timing of clopidogrel discontinuation with both your surgeon and cardiologist.
What Is the Correct Dosage of Clopidogrel Teva?
Clopidogrel Teva should always be used exactly as your doctor has instructed. The dosage varies depending on the clinical indication, and both loading doses and maintenance doses may be required. Take the tablet at approximately the same time each day, with or without food. Swallow the tablet whole with a glass of water.
Adults
| Indication | Loading Dose | Maintenance Dose | Typical Duration |
|---|---|---|---|
| Recent MI / Ischaemic Stroke / PAD | None | 75 mg once daily | Long-term (indefinite) |
| NSTE-ACS (with aspirin) | 300 mg single dose | 75 mg once daily + aspirin 75–100 mg | Up to 12 months |
| STEMI with fibrinolysis (with aspirin) | 300 mg (age ≤75) or none (age >75) | 75 mg once daily + aspirin 75–325 mg | Up to 12 months |
| PCI with stent (with aspirin) | 300–600 mg single dose | 75 mg once daily + aspirin 75–100 mg | 6–12 months (varies by stent type and risk) |
The loading dose is given to achieve rapid platelet inhibition in acute clinical settings. A 300 mg loading dose provides significant antiplatelet activity within 2 to 6 hours, while a 600 mg loading dose achieves therapeutic platelet inhibition more rapidly (within approximately 2 hours). The 600 mg loading dose is commonly used in the context of PCI, as recommended by ESC guidelines. In STEMI patients over 75 years of age receiving fibrinolytic therapy, no loading dose is given due to increased bleeding risk in this population.
Dual antiplatelet therapy (DAPT) with clopidogrel 75 mg and aspirin 75–100 mg daily is the standard of care after acute coronary syndrome and stent implantation. The recommended duration of DAPT depends on several factors, including the clinical presentation (stable vs. acute coronary syndrome), the type of stent implanted, and the patient's individual bleeding and ischaemic risk profiles. ESC 2023 guidelines recommend assessing the benefit-risk balance at regular intervals and potentially shortening or prolonging DAPT duration based on validated risk scores.
Children and Adolescents
Clopidogrel is not generally recommended for use in children and adolescents under 18 years of age. Experience in this age group is very limited. In certain specialized clinical scenarios (such as after paediatric cardiac stenting or in children with Kawasaki disease), clopidogrel may be prescribed by paediatric cardiologists, but this represents off-label use and requires careful risk-benefit assessment. The CLARINET trial studied clopidogrel in neonates and infants with cyanotic congenital heart disease but did not demonstrate a significant benefit over placebo in the primary endpoint.
Elderly Patients
No dose adjustment is required for elderly patients. In clinical trials, including the CURE and CAPRIE studies, elderly patients were included and the safety and efficacy profile was consistent with that observed in younger adults. However, elderly patients are generally at higher risk of both ischaemic and bleeding events, and more vigilant monitoring is recommended. In STEMI patients over 75 years, the loading dose is omitted when clopidogrel is used with fibrinolytic therapy, as noted above.
Missed Dose
If you forget to take a dose of clopidogrel, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a forgotten dose. If you are unsure about what to do, consult your doctor or pharmacist. Setting a daily reminder on your phone or using a pill organizer can help you maintain a consistent dosing schedule.
Overdose
If you take more clopidogrel than prescribed, contact your doctor, pharmacist, or emergency services immediately. Overdose with clopidogrel may lead to prolonged bleeding time and subsequent bleeding complications. There is no specific antidote for clopidogrel overdose. If rapid reversal of the antiplatelet effect is needed (for example, in the setting of life-threatening bleeding or emergency surgery), platelet transfusion may be required. Supportive treatment should be administered as necessary. Because clopidogrel's active metabolite binds irreversibly to platelets, haemodialysis is not expected to be useful.
What Are the Side Effects of Clopidogrel Teva?
Like all medicines, clopidogrel can cause side effects, although not everybody gets them. The most important side effect to be aware of is bleeding, which is a direct consequence of the drug's antiplatelet mechanism of action. Bleeding can occur at any site in the body and ranges from minor bruising to life-threatening haemorrhage. The risk of bleeding is increased when clopidogrel is used in combination with aspirin (dual antiplatelet therapy) or with anticoagulants.
Contact your doctor immediately if you experience any of the following: blood in your stools (appearing as black or tar-like stools), blood in your urine, vomiting blood or material that looks like coffee grounds, coughing up blood, unexplained or excessive bruising, bleeding that does not stop with usual pressure, or signs of stroke (sudden weakness, numbness, confusion, vision changes, or severe headache).
Common
- Bruising (haematoma)
- Nosebleeds (epistaxis)
- Gastrointestinal bleeding (stomach or intestinal)
- Diarrhoea
- Abdominal pain
- Dyspepsia (indigestion)
- Bleeding at puncture sites
Uncommon
- Headache
- Dizziness and paraesthesia (tingling)
- Gastric ulcer and duodenal ulcer
- Gastritis (stomach inflammation)
- Vomiting, nausea, constipation, flatulence
- Rash, pruritus (itching)
- Blood in urine (haematuria)
- Prolonged bleeding time
- Decreased neutrophils (neutropenia) or platelets (thrombocytopenia)
Rare
- Severe neutropenia (agranulocytosis)
- Severe thrombocytopenia (platelet count below 30,000)
- Thrombotic thrombocytopenic purpura (TTP)
- Intracranial bleeding (bleeding in the brain)
- Retroperitoneal haemorrhage
- Severe skin reactions (Stevens-Johnson syndrome, erythema multiforme)
- Hepatitis (liver inflammation)
- Acute liver failure
- Interstitial pneumonitis
- Vasculitis (inflammation of blood vessels)
- Serum sickness-like reaction
- Angioedema
The risk of bleeding with clopidogrel is dose-dependent and increases when combined with other antiplatelet agents or anticoagulants. In the CURE trial, major bleeding occurred in 3.7% of patients receiving clopidogrel plus aspirin compared with 2.7% in the aspirin-alone group over a mean treatment period of 9 months. Life-threatening bleeding occurred in 2.2% versus 1.8%, respectively. The excess risk of bleeding must be weighed against the significant reduction in ischaemic events (cardiovascular death, myocardial infarction, or stroke) that dual antiplatelet therapy provides.
Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal complication that has been reported with clopidogrel, particularly during the first two weeks of therapy. TTP is characterised by thrombocytopenia (low platelet count), microangiopathic haemolytic anaemia (destruction of red blood cells), neurological symptoms, renal dysfunction, and fever. Early recognition is critical, as TTP requires emergency treatment with plasma exchange (plasmapheresis). The estimated incidence is approximately 4 cases per million patients exposed.
If you experience any side effects, including those not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority (such as the Yellow Card Scheme in the UK, MedWatch in the US, or the relevant authority in your country). By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Clopidogrel Teva?
Store Clopidogrel Teva tablets at a temperature not exceeding 30°C (86°F). Keep the tablets in the original blister pack or bottle to protect them from moisture and light. Do not transfer tablets to a different container unless it provides equivalent protection.
Keep this medicine out of the sight and reach of children. Store it in a secure location, away from areas where children can access it. Do not use this medicine after the expiry date stated on the carton, blister pack, or bottle label. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment. In many countries, pharmacies accept unused medications for safe disposal.
What Does Clopidogrel Teva Contain?
The active substance is clopidogrel. Each film-coated tablet contains 75 mg of clopidogrel (as clopidogrel hydrogen sulfate, equivalent to 97.875 mg clopidogrel hydrogen sulfate).
The other ingredients (excipients) are:
- Tablet core: Microcrystalline cellulose, hydroxypropylcellulose (low-substituted), mannitol (E421), crospovidone (type A), citric acid monohydrate, macrogol 6000, stearic acid, hydrogenated castor oil.
- Film coating: Hypromellose (E464), iron oxide red (E172), lactose monohydrate, titanium dioxide (E171), triacetin.
Clopidogrel Teva 75 mg film-coated tablets are round, biconvex, pink-coloured, film-coated tablets. They may be debossed with identification markings depending on the specific manufacturing batch and regional packaging. The tablets are available in blister packs of 14, 28, 30, 50, 84, 90, or 100 tablets, or in bottles. Not all pack sizes may be marketed in your country.
The film coating of Clopidogrel Teva tablets contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. However, the amount of lactose in the film coating is very small, and most patients with common lactose intolerance can take the tablet without issues. Discuss any concerns with your doctor or pharmacist.
Frequently Asked Questions About Clopidogrel Teva
Clopidogrel Teva and Plavix contain the same active ingredient (clopidogrel 75 mg) and are therapeutically equivalent. Clopidogrel Teva is a generic formulation manufactured by Teva Pharmaceuticals, while Plavix is the original branded product developed by Sanofi. Generic medicines must meet strict bioequivalence standards set by regulatory agencies (EMA, FDA) to demonstrate that they deliver the same amount of active substance at the same rate as the original product. In clinical terms, there is no difference in efficacy or safety between the two products.
Moderate alcohol consumption (up to one standard drink per day for women, up to two for men) is generally considered acceptable while taking clopidogrel. However, excessive alcohol consumption increases the risk of gastrointestinal bleeding, which is already elevated with clopidogrel use. Chronic heavy drinking also affects liver function and may alter the metabolism of clopidogrel. It is advisable to discuss your alcohol consumption with your doctor, particularly if you are also taking aspirin as part of dual antiplatelet therapy.
Suddenly stopping clopidogrel without medical advice can be very dangerous, particularly if you have a coronary stent. Premature discontinuation is the strongest independent risk factor for stent thrombosis, a condition where a blood clot forms inside the stent, potentially causing a massive heart attack that can be fatal. Even in patients without stents, abrupt cessation of clopidogrel may lead to a rebound increase in platelet reactivity and heightened risk of atherothrombotic events. Always consult your cardiologist before stopping or interrupting clopidogrel treatment.
Clopidogrel is commonly referred to as a "blood thinner," but technically it is an antiplatelet agent, not an anticoagulant. Antiplatelet drugs (like clopidogrel and aspirin) work by preventing platelets from clumping together, which helps prevent clots in arteries. True anticoagulants (like warfarin, heparin, or DOACs) work by interfering with the coagulation cascade, a different mechanism of clot formation. Both reduce the ability of blood to clot, but they target different pathways and are used for different clinical indications.
Yes. Pharmacogenomic testing for CYP2C19 variants can identify patients who are poor metabolizers (approximately 2% of Caucasians, up to 15% of Asians) and who may not adequately convert clopidogrel to its active metabolite. These patients have reduced platelet inhibition and may be at higher risk of cardiovascular events, particularly stent thrombosis. The FDA label for clopidogrel includes a boxed warning about diminished effectiveness in poor metabolizers. If testing reveals poor metabolizer status, your doctor may prescribe an alternative P2Y12 inhibitor such as prasugrel or ticagrelor, which do not require CYP2C19 for activation. Guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) provide specific dosing recommendations based on CYP2C19 genotype.
For minor dental procedures (fillings, scaling, simple extractions), clopidogrel generally does not need to be stopped. Local haemostatic measures (gauze, sutures, tranexamic acid mouthwash) are usually sufficient to manage any increased bleeding. For more complex procedures (multiple extractions, surgical extractions, implant placement), your dentist should consult with your cardiologist about the need to temporarily interrupt clopidogrel 5–7 days before the procedure. The decision depends on the balance between bleeding risk from the procedure and thrombotic risk from stopping the medication. Never stop clopidogrel on your own; always follow the joint advice of your dentist and cardiologist.
References
- European Medicines Agency (EMA). Clopidogrel Teva – Summary of Product Characteristics. Updated 2025.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE). N Engl J Med. 2001;345(7):494-502.
- Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction (COMMIT/CCS-2). Lancet. 2005;366(9497):1607-1621.
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826.
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. J Am Coll Cardiol. 2022;79(2):e21-e129.
- World Health Organization. WHO Model List of Essential Medicines. 23rd List, 2023.
- U.S. Food and Drug Administration. Plavix (clopidogrel bisulfate) Prescribing Information. Updated 2024.
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-323.
- Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease (COGENT). N Engl J Med. 2010;363(20):1909-1917.
Medical Editorial Team
This article has been developed and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialist qualifications in cardiology, clinical pharmacology, and haematology.
Medical Content
Written by specialist physicians in cardiology and clinical pharmacology
Medical Review
Reviewed by the iMedic Medical Review Board according to ESC, AHA/ACC, and WHO guidelines
Evidence Standard
Evidence Level 1A – based on systematic reviews and landmark RCTs (CAPRIE, CURE, COMMIT)
Independence
No pharmaceutical funding. All content is editorially independent.
Last medical review: | Published: